Altshuler Shaham Ltd Acquires Shares of 163,200 Haleon plc (NYSE:HLN)

Altshuler Shaham Ltd purchased a new stake in shares of Haleon plc (NYSE:HLN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 163,200 shares of the company’s stock, valued at approximately $1,348,000.

A number of other hedge funds also recently added to or reduced their stakes in HLN. Janney Montgomery Scott LLC increased its holdings in Haleon by 182.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company’s stock worth $3,726,000 after buying an additional 283,410 shares in the last quarter. Capstone Investment Advisors LLC purchased a new stake in Haleon during the 1st quarter valued at $1,969,000. Wellington Management Group LLP lifted its holdings in shares of Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after buying an additional 8,423,475 shares during the period. Douglas Lane & Associates LLC boosted its stake in shares of Haleon by 2.1% in the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock worth $71,332,000 after buying an additional 175,082 shares during the last quarter. Finally, Procyon Advisors LLC boosted its stake in shares of Haleon by 559.9% in the 1st quarter. Procyon Advisors LLC now owns 131,665 shares of the company’s stock worth $1,118,000 after buying an additional 111,713 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Performance

NYSE:HLN opened at $10.52 on Monday. The stock has a 50-day simple moving average of $9.76 and a two-hundred day simple moving average of $8.88. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 52-week low of $7.70 and a 52-week high of $10.76. The firm has a market capitalization of $48.04 billion, a PE ratio of 35.07, a P/E/G ratio of 3.10 and a beta of 0.26.

Haleon (NYSE:HLN) last released its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $3.50 billion during the quarter, compared to analysts’ expectations of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same period in the prior year, the company posted $0.08 earnings per share. Analysts forecast that Haleon plc will post 0.46 EPS for the current year.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were issued a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 1.6%. Haleon’s dividend payout ratio is presently 33.33%.

Analyst Ratings Changes

HLN has been the subject of a number of research reports. Berenberg Bank started coverage on Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. Morgan Stanley boosted their price target on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday. Finally, The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.